Abstract:
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
Abstract:
The present invention is based on the discovery of a process for preparing pyrimidin- dione compounds, especially alogliptin and its derivatives, which comprises the reaction of a urea derivative of formula (VIII) with a malonic acid or its derivatives to form intermediates of formulae (VII) or (VII-A), which are subsequently converted to a compound of formula (II) upon introduction of a leaving group X. Compound (II) then reacts with an amine to form compound (I), which is optionally converted to its salts of formula (IV).
Abstract:
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders.
Abstract:
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocyline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Abstract:
New classes of urea/ureido functional compounds of formula (I), wherin Y is (a), (b) or (c), wherein A is (d), (e) or (f), wherein B is (g), (h) or (i), and compositions containing the same are disclosed which are particularly suitable for use as monomers for imparting wet adhesion and/or self-crosslinking properties to polymers, especially in aqueous emulsion systems used to make latex paints. Compositions containing the same, as well as additional uses thereof are also disclosed.
Abstract:
L'invention concerne le domaine des compositions de polyisocyanates pour la préparation de revêtements et d'adhésifs. La composition selon l'invention combine un composé polyisocyanate à motifs biuret, un composé diluant réactif polaire, protique, un de leurs composés d'addition et un composé diluant réactif aprotique. L'invention concerne également un procédé de préparation de la composition selon l'invention ainsi que son utilisation pour la préparation d'un revêtement ou d'un adhésif.
Abstract:
N-(2-hydroxyalkanoyl) -N, N' -dialkylureas of general formula (I) are described A-X-(A) n , where A: m = 0 or m = 1; when m = 0, X = R''' , where R''' is an aliphatic, cycloaliphatic, arylaliphatic radical, C 1 -C 18 ; when m = 1, X = -(CH 2 ) n -, where n is an integer from 1 and 20, preferably from 2 to 6; R is chosen among H, and alkyl radicals C 1 -C 8 , possibly substituted with halogen atoms; R' is an aliphatic, cycloaliphatic, arylaliphatic radical, C 1 -C 18 ; R'' is chosen among H, aliphatic, cycloaliphatic, arylaliphatic radical, C 1 -C 18 . The preparation of said compounds is described, as well as the preparation of corresponding polymers.
Abstract:
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunological diseases and cancer.
Abstract:
Compounds fo the formula (I) wherein R and R are independently hydrogen or substituents; R is lower alkyl having from 2 to 4 carbon atoms or a 5 to 7-membered ring which is cycloalkyl, cycloalkenyl, or heterocycloalkyl having one heteroatom selected from oxygen and sulfur; R is -C(O)NHR , or is R ; R is a heteroaromatic ring connected by a ring carbon atom to the amide group and having nitrogen adjacent to the connecting ring carbon atom; and X is oxygen, sulfur, sulfonyl of carbonyl; are glucokinase acitvators useful for treating type II diabetes.
Abstract translation:式(I)的化合物,其中R 1和R 2独立地是氢或取代基; R 3是具有2至4个碳原子的低级烷基或5至7元环,其是具有一个选自氧和硫的杂原子的环烷基,环烯基或杂环烷基; R 4是-C(O)NHR 5或R 6; R 6是由环碳原子连接到酰胺基并且具有与连接环碳原子相邻的氮的杂芳环; X为氧,硫,羰基磺酰基; 是可用于治疗II型糖尿病的葡萄糖激酶引发剂。
Abstract:
This invention relates to ethylenically unsaturated polymerizable monomers of formula (I) wherein Y is (a, b, c, d, e, f, g, h or i) wherein A is (j, k, l, m, n or o) wherein each R is individually H, -(-CqH2q-O-)m-R , (p), etc., which are particularly suitable for use as wet adhesion promoters and in the preparation of self-crosslinking polymers. More specifically, the polymerizable monomers of the present invention are useful to promote adhesion in polymers and copolymers, and especially in aqueous emulsion copolymer latices which are used to prepare latex paints, as well as in the preparation of self-crosslinking polymers for coating systems.